benzotriazol-1-yl-(2,2,6,6-tetramethyltetrahydropyran-4-yl)methanone | 1567335-31-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 英文名称: benzotriazol-1-yl-(2,2,6,6-tetramethyltetrahydropyran-4-yl)methanone
• 英文别名: Benzotriazol-1-yl-(2,2,6,6-tetramethyl-tetrahydro-pyran-4-yl)-methanone；benzotriazol-1-yl-(2,2,6,6-tetramethyloxan-4-yl)methanone
• CAS: 1567335-31-2
• 化学式: C₁₆H₂₁N₃O₂
• 分子量: 287.362
• InChiKey: RSBPPPOGGCNCNP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.56
• 拓扑面积：
  57
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  benzotriazol-1-yl-(2,2,6,6-tetramethyltetrahydropyran-4-yl)methanone 在 四(三苯基膦)钯 、 magnesium dibromide 、 sodium carbonate 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 乙醇 、 二氯甲烷 、 1,2-二氯乙烷 、 甲苯 为溶剂， 生成 2-[5-(4-chlorophenyl)-3-(2,2,6,6-tetramethyltetrahydro-2H-pyran-4-yl)-1H-pyrazol-1-yl]-N-ethylaniline
  参考文献：
  名称：

  Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Cav 2.2) blockers for the treatment of pain

  摘要：

  A novel series of pyrazolyltetrahydropyran N-type calcium channel blockers are described. Structural modifications of the series led to potent compounds in both a cell-based fluorescent calcium influx assay and a patch clamp electrophysiology assay. Representative compounds from the series were bioavailable and showed efficacy in the rat CFA and CCI models of inflammatory and neuropathic pain.

  DOI：

  10.1016/j.bmcl.2018.10.007
• 作为产物：
  描述：

  2,2,6,6-四甲基-2H-3,5,6-三氢吡喃-4-酮 在 氯化亚砜 、 potassium tert-butylate 作用下， 以 乙二醇二甲醚 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 8.0h， 生成 benzotriazol-1-yl-(2,2,6,6-tetramethyltetrahydropyran-4-yl)methanone
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  [FR] PYRAZOLES SUBSTITUÉS SERVANT DE BLOQUEURS DE CANAL CALCIQUE DE TYPE N

  摘要：

  本发明涉及式(I)化合物，其中X1、X2、X3、X4、R1、R2、R3和Q如本文所述定义，用作N型钙通道阻断剂。

  公开号：

  WO2014028803A1

文献信息

• [EN] SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS<br/>[FR] PYRAZOLES SUBSTITUÉS SERVANT DE BLOQUEURS DE CANAL CALCIQUE DE TYPE N
  申请人：JANSSEN PHARMACEUTICA NV

  公开号：WO2014028803A1

  公开（公告）日：2014-02-20

  The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.

  本发明涉及式(I)化合物，其中X1、X2、X3、X4、R1、R2、R3和Q如本文所述定义，用作N型钙通道阻断剂。
• SUBSTITUTED PYRAZOLES AS N-TYPE CALCIUM CHANNEL BLOCKERS
  申请人：Janssen Pharmaceutica NV

  公开号：US20140163031A1

  公开（公告）日：2014-06-12

  The present invention relates to compounds of Formula (I), wherein X 1 , X 2 , X 3 , X 4 , R 1 , R 2 , R 3 , and Q are as defined herein, useful as N-type calcium channel blockers.

  本发明涉及式(I)的化合物，其中X1、X2、X3、X4、R1、R2、R3和Q的定义如本文所述，作为N型钙通道阻滞剂有用。
• Substituted pyrazoles as N-type calcium channel blockers
  申请人：Janssen Pharmaceutica NV

  公开号：US08901314B2

  公开（公告）日：2014-12-02

  The present invention relates to compounds of Formula (I), wherein X1, X2, X3, X4, R1, R2, R3, and Q are as defined herein, useful as N-type calcium channel blockers.

  本发明涉及式(I)的化合物，其中X1，X2，X3，X4，R1，R2，R3和Q如本文所定义，可用作N型钙通道阻滞剂。
• US8901314B2
  申请人：——

  公开号：US8901314B2

  公开（公告）日：2014-12-02
• Discovery and optimization of a novel series of pyrazolyltetrahydropyran N-type calcium channel (Cav 2.2) blockers for the treatment of pain
  作者：Mark J. Wall、Nalin L. Subasinghe、Michael P. Winters、Mary Lou Lubin、Michael F.A. Finley、Ning Qin、Michael R. Brandt、Michael P. Neeper、Craig R. Schneider、Raymond W. Colburn、Christopher M. Flores、Zhihua Sui

  DOI：10.1016/j.bmcl.2018.10.007

  日期：2018.12

  A novel series of pyrazolyltetrahydropyran N-type calcium channel blockers are described. Structural modifications of the series led to potent compounds in both a cell-based fluorescent calcium influx assay and a patch clamp electrophysiology assay. Representative compounds from the series were bioavailable and showed efficacy in the rat CFA and CCI models of inflammatory and neuropathic pain.